After 800+ hours of research, the evidence for statin drugs is far weaker than commonly presented. The benefits in primary prevention are marginal; the risks and side effects are systematically understated.

The Primary Prevention Evidence

"For primary prevention, 100 people must take statins for 5 years to prevent 1 cardiovascular event. 99 people receive no benefit but all 100 are exposed to the risks."

"Cochrane Collaboration"

Primary prevention refers to preventing cardiovascular events in people who have not yet had a heart attack or stroke. This is where statins are most widely prescribed — and where the evidence is weakest.

A 2015 Cochrane review of statin primary prevention trials found:

  • Absolute risk reduction: approximately 1% over 5 years
  • Number needed to treat: approximately 100 people for 5 years to prevent 1 cardiovascular event
  • No significant reduction in all-cause mortality in low-risk individuals

This means that 99 out of 100 people taking statins for primary prevention receive no cardiovascular benefit — but all 100 are exposed to the risks.

99 out of 100 people taking statins for primary prevention receive no cardiovascular benefit. But all 100 are exposed to the risks of muscle damage, cognitive impairment, and increased diabetes risk.

The Side Effect Problem

Statin side effects are systematically understated in industry-funded trials. The most common side effects include:

Muscle problems: Myalgia (muscle pain) affects 5-10% of statin users in clinical practice, though industry-funded trials report lower rates. Rhabdomyolysis (severe muscle breakdown) is rare but life-threatening.

Cognitive impairment: Multiple case reports and observational studies link statin use to memory problems and cognitive decline. The FDA added a warning about cognitive impairment to statin labels in 2012.

Increased diabetes risk: A 2010 meta-analysis found that statin use increases the risk of type-2 diabetes by 9%. The JUPITER trial, which showed cardiovascular benefit, also showed a 25% increase in diabetes risk.

CoQ10 depletion: Statins block the mevalonate pathway, which produces both cholesterol and CoQ10. CoQ10 is essential for mitochondrial energy production. Statin-induced CoQ10 depletion may explain the muscle and cognitive side effects.

The Secondary Prevention Evidence

Statins do have meaningful benefit in secondary prevention — in people who have already had a heart attack. In this high-risk population, the absolute risk reduction is larger (approximately 3-5% over 5 years), and the benefit-risk ratio is more favorable.

The Niacin Alternative

Niacin (vitamin B3) has better evidence for cardiovascular benefit than statins in several respects:

  • Raises HDL (statins do not)
  • Lowers triglycerides (statins have modest effect)
  • Reduces Lp(a) (statins do not)
  • Has been shown to reduce cardiovascular events in the Coronary Drug Project

Niacin costs pennies per day. Statins cost $100-300 per month. Yet statins are prescribed to 40 million Americans while niacin is rarely recommended.